ERBB2 and breast carcinoma: The pooled clinical dataset of 394 ER-positive primary breast cancers were subjected to GSEA to identify clinical parameters (patient age at diagnosis, tumor grade, PR, ERBB2, and nodal status) potentially associated with the five derived gene signatures, as well as previously reported gene signatures representing sustained estrogen induction [29], luminal subtype [40], MAPK activation [28], and tumor proliferation [39].